-
In the Moment- Spring 2019
Readers share snapshots of their lives today.
-
In the Moment- Winter 2018/2019
Readers share snapshots of their lives today.
-
Survivor Profile
The Bridge BuilderBreast cancer survivor Bob Riter forges connections among people affected by all types of cancer.
by Marci A. Landsmann
-
Q&A
Dissecting Mental IllnessNeuroscientist Barbara Lipska describes her experiences with symptoms of psychiatric illness caused by treatment for metastases in her brain.
by Marci A. Landsmann
-
In the Moment- Fall 2018
Tanya Waring-Hearn, Amy Rowley, Elsie Young.
-
Survivor Profile
The Power of PatientsJanet Freeman-Daily helps put patients at the center of lung cancer research.
by Robin Meadows
-
Raising Their Voices
People with metastatic breast cancer are demanding to be seen, counted and included in breast cancer research.
by Sue Rochman
-
Learning to Share
At first, I wanted to hide my cancer diagnosis. My son showed me what a mistake that was.
by Lenn Robbins
-
Being Candid About Cancer
As a father with an aggressive brain cancer, I've opted against elaborate metaphors and in favor of candid speech when talking about cancer with my children.
by Adam Hayden
-
Survivor Profile
A Long Road BackMultiple myeloma survivor Gary Lambert deploys inventiveness and fortitude to deal with cancer.
by Lindsey Konkel
Cancer Talk
Researchers Tackle Immune-related Adverse Effects
Scientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.
by Marci A. Landsmann
Tissue and Liquid Biopsy for Targeted TherapyTailored treatments led to better outcomes than standard of care when biomarker results from liquid biopsy and tumor tissue aligned.
by Eric Fitzsimmons
Cancer Vaccines Show Promise in Early TrialsWhile mRNA vaccines offer a personalized approach to triggering an immune response, peptide vaccines could be a one-size-fits-all treatment. Researchers are exploring both options.
by Thomas Celona
Declining Breast Cancer Mortality in Younger WomenU.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.
by Kevin McLaughlin